Online inquiry

IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6714MR)

This product GTTS-WQ6714MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6714MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ541MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ2030MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ520MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 4D11
GTTS-WQ2334MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ7135MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ14553MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ2773MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ4588MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW